Eli Lilly
4/10
Risk level moved from Low Risk to Medium Risk. Score changed by 2 points as of 2026-07-05.
Eli Lilly carries $29.5B in long-term debt, with $39.4B in scheduled principal maturities. DebtCanary scores LLY at 4/10, indicating moderate refinancing pressure.
Maturity Schedule
| Period | Amount Due |
|---|---|
| Year 1 (0-12 months) | N/A |
| Year 2 (12-24 months) | N/A |
| Year 3 (24-36 months) | N/A |
| Year 4 (36-48 months) | N/A |
| Year 5 (48-60 months) | N/A |
| Beyond 5 Years | $39.4B |
| Total Scheduled Maturities | $39.4B |
Key Metrics
Score Components
| Component | Value |
|---|---|
| Near-Term Maturity Concentration | N/A |
| Interest Coverage Ratio | N/A |
| Debt-to-Equity Ratio | 0.94 |
| Cash Coverage of Near-Term Debt | 1.32x |
Recent SEC Filings
Material disclosures from Eli Lilly's most recent EDGAR filings. 8-K item labels indicate the type of event reported.
| Date | Form | Details |
|---|---|---|
| 2026-05-20 | 8-K | Other Events |
| 2026-05-08 | 424B2 | Prospectus supplement — possible debt or equity issuance |
| 2026-05-07 | 8-K | Shareholder Vote |
| 2026-05-06 | 424B2 | Prospectus supplement — possible debt or equity issuance |
| 2026-04-30 | 10-Q | Quarterly report |
| 2026-04-30 | 8-K | Earnings Results |
| 2026-03-20 | DEFA14A | Additional proxy materials |
| 2026-03-20 | DEF 14A | Proxy statement |
Related Companies
Data Source:
Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports).
Fiscal period end: 2026-03-31.
Filing date: 2026-04-30.
Data last fetched: 2026-07-05.
Maturity schedules reflect the company's most recently reported debt repayment obligations.
Data quality: Partial.
View SEC EDGAR filings for Eli Lilly →